Quintrio
Home

SERVICES-HOME HEALTH CARE SERVICES

BrightSpring Health Services, Inc. Common Stock

BTSG

BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services, and others. It generates the majority of its revenue from the Pharmacy Solutions segment.

Last trade $69.64
Day change -$1.73 (-2.42%)
Day range $69.41 – $72.11
Volume 819,649
Market cap $14.20B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$14.2B
Price / earnings
34.61×
Price / book
6.52×
Price / sales
0.93×
EV / sales
1.03×
EV / EBITDA
23.1×

Profitability

Earnings per share
$2.06
Return on assets
6.55%
Return on equity
18.85%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.01×
Current ratio
1.62×
Quick ratio
1.22×
Cash ratio
0.42×

Cash flow

Price / cash flow
23.56×
Price / free cash flow
28.84×
Free cash flow
$492.41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BTSG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$4.21B$3.87B$3.61B$3.55B$3.33B$3.15B$2.88B$2.75B
Cost of revenue$3.69B$3.38B$3.13B$3.14B$2.94B$2.77B$2.54B$2.41B
Gross profit$518.55M$492.75M$482.22M$412.55M$392.01M$374.85M$338.37M$338.67M
Selling, general and administrative$358.07M$362.36M$360.77M$304.44M$304.17M$326.3M$287.63M$283.13M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$358.07M$362.36M$360.77M$304.44M$304.17M$326.3M$287.63M$283.13M
Operating income$160.48M$130.39M$121.45M$108.11M$87.84M$48.56M$50.74M$55.54M
Interest expense-$31.04M-$36.88M-$38.62M-$38.54M-$38.24M-$38.78M-$41.76M-$46.18M
Income before taxes$129.44M$93.51M$82.83M$69.58M$49.61M$9.78M$8.98M$9.36M
Income taxes$28.64M$6.91M$8.55M$20.03M$12.12M$1.24M-$240K$5.08M
Net income$100.3M$84.21M$148.61M$77.32M$55.24M$27.54M$29.01M$15.4M
Net income attributable to common shareholders$100.14M$84.29M$148.77M$77.08M$55.84M$28.21M$29.54M$16M
EBITDA$198.85M$171.81M$160.54M$147.64M$128.6M$90.4M$92.9M$110.42M
Basic earnings per share$0.48$0.41$0.73$0.38$0.27$0.14$0.15$0.08
Diluted earnings per share$0.45$0.38$0.67$0.34$0.26$0.13$0.14$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MDT Q2 Earnings Preview: Will Cardiovascular Performance Lift Results?

Medtronic is expected to report Q2 fiscal 2027 results on November 24, with revenues projected to grow 5.7% to $9.47 billion and EPS estimated at $1.34 (down 1.5% YoY). The Cardiovascular segment is expected to drive growth at 9.6%, supported by cardiac ablation, CRM, and structural heart products. Diabetes revenues are projected to grow 12.9% following the MiniMed separation. However, the company has a negative Earnings ESP of -0.75%, suggesting limited upside surprise potential.

Zacks Investment Research

The Zacks Analyst Blog Highlights Quanta, BrightSpring Health, Phillips 66, Valero Energy and HF Sinclair

Zacks equity research analysts identified five growth stocks with Zacks Rank #1 (Strong Buy) ratings and Growth Score of A for November investment: Quanta Services, BrightSpring Health Services, Phillips 66, Valero Energy, and HF Sinclair. These stocks are positioned to benefit from infrastructure spending, AI data center expansion, refining fundamentals, and renewable energy trends.

Zacks Investment Research

Buy 5 Growth Stocks to Enhance Your Portfolio Returns in November

Zacks Investment Research identifies five growth stocks with Strong Buy ratings and A Growth Scores as attractive November purchases: Quanta Services (PWR), BrightSpring Health Services (BTSG), Phillips 66 (PSX), Valero Energy (VLO), and HF Sinclair (DINO). These stocks benefit from infrastructure demand, healthcare expansion, refining strength, and renewable energy initiatives, with expected earnings growth ranging from 62.7% to over 100% for the current year.

Zacks Investment Research

BTSG vs. CAI: Which Stock Should Value Investors Buy Now?

In a comparison of two Medical Services sector stocks, BrightSpring Health Services (BTSG) emerges as the better value investment option compared to Caris Life Sciences (CAI). BTSG holds a Zacks Rank of #1 (Strong Buy) with a forward P/E of 35.08 and Value grade of B, while CAI has a Zacks Rank of #3 (Hold) with a forward P/E of 234.70 and Value grade of D. BTSG's superior earnings estimate revisions and more attractive valuation metrics make it the preferred choice for value investors.

Zacks Investment Research

Why Fast-paced Mover BrightSpring Health Services, Inc. (BTSG) Is a Great Choice for Value Investors

BrightSpring Health Services (BTSG) is highlighted as an attractive investment opportunity combining momentum with value. The stock has gained 5.4% over four weeks and 8.8% over 12 weeks, with a beta of 1.77 indicating high volatility. Despite strong momentum, BTSG trades at a reasonable valuation with a Price-to-Sales ratio of 0.88x, earning a Zacks Rank #1 (Strong Buy) rating based on upward earnings estimate revisions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.